CONSENSUS RECOMMENDATIONS: Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: Consensus recommendations from the North American Menopause Society and the International Society for the Study of Women's Sexual Health

Stephanie S. Faubion, Lisa C. Larkin, Cynthia A. Stuenkel, Gloria A. Bachmann, Lisa A. Chism, Risa Kagan, Andrew M. Kaunitz, Michael L. Krychman, Sharon J. Parish, Ann H. Partridge, Joann V. Pinkerton, Tami S. Rowen, Marla Shapiro, James A. Simon, Shari B. Goldfarb, Sheryl A. Kingsberg

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. The Expert Consensus Panel is comprised of a diverse group of 16 multidisciplinary experts well respected in their fields. The panelists individually conducted an evidence-based review of the literature in their respective areas of expertise. They then met to discuss the latest treatment options for genitourinary syndrome of menopause (GSM) in survivors of breast cancer and review management strategies for GSM in women with or at high risk for breast cancer, using a modified Delphi method. This iterative process involved presentations summarizing the current literature, debate, and discussion of divergent opinions concerning GSM assessment and management, leading to the development of consensus recommendations for the clinician. Genitourinary syndrome of menopause is more prevalent in survivors of breast cancer, is commonly undiagnosed and untreated, and may have early onset because of cancer treatments or risk-reducing strategies. The paucity of evidence regarding the safety of vaginal hormone therapies in women with or at high risk for breast cancer has resulted in avoidance of treatment, potentially adversely affecting quality of life and intimate relationships. Factors influencing decision-making regarding treatment for GSM include breast cancer recurrence risk, severity of symptoms, response to prior therapies, and personal preference. We review current evidence for various pharmacologic and nonpharmacologic therapeutic modalities in women with a history of or at high risk for breast cancer and highlight the substantial gaps in the evidence for safe and effective therapies and the need for future research. Treatment of GSM is individualized, with nonhormone treatments generally being first line in this population. The use of local hormone therapies may be an option for some women who fail nonpharmacologic and nonhormone treatments after a discussion of risks and benefits and review with a woman's oncologist. We provide consensus recommendations for an approach to the management of GSM in specific patient populations, including women at high risk for breast cancer, women with estrogen-receptor positive breast cancers, women with triple-negative breast cancers, and women with metastatic disease.

Original languageEnglish (US)
Pages (from-to)596-608
Number of pages13
JournalMenopause
Volume25
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Menopause
Consensus
Breast Neoplasms
Therapeutics
Survivors
Point-of-Care Systems
Quality of Life
Hormones
Triple Negative Breast Neoplasms
Estrogen Receptors
Health Personnel
Population
Decision Making
Safety
Recurrence

Keywords

  • Atrophic vaginitis
  • Breast cancer
  • Breast cancer risk
  • Breast cancer survivors
  • Genitourinary syndrome of menopause
  • Vulvovaginal atrophy

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

CONSENSUS RECOMMENDATIONS : Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: Consensus recommendations from the North American Menopause Society and the International Society for the Study of Women's Sexual Health. / Faubion, Stephanie S.; Larkin, Lisa C.; Stuenkel, Cynthia A.; Bachmann, Gloria A.; Chism, Lisa A.; Kagan, Risa; Kaunitz, Andrew M.; Krychman, Michael L.; Parish, Sharon J.; Partridge, Ann H.; Pinkerton, Joann V.; Rowen, Tami S.; Shapiro, Marla; Simon, James A.; Goldfarb, Shari B.; Kingsberg, Sheryl A.

In: Menopause, Vol. 25, No. 6, 01.06.2018, p. 596-608.

Research output: Contribution to journalReview article

Faubion, SS, Larkin, LC, Stuenkel, CA, Bachmann, GA, Chism, LA, Kagan, R, Kaunitz, AM, Krychman, ML, Parish, SJ, Partridge, AH, Pinkerton, JV, Rowen, TS, Shapiro, M, Simon, JA, Goldfarb, SB & Kingsberg, SA 2018, 'CONSENSUS RECOMMENDATIONS: Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: Consensus recommendations from the North American Menopause Society and the International Society for the Study of Women's Sexual Health', Menopause, vol. 25, no. 6, pp. 596-608. https://doi.org/10.1097/GME.0000000000001121
Faubion, Stephanie S. ; Larkin, Lisa C. ; Stuenkel, Cynthia A. ; Bachmann, Gloria A. ; Chism, Lisa A. ; Kagan, Risa ; Kaunitz, Andrew M. ; Krychman, Michael L. ; Parish, Sharon J. ; Partridge, Ann H. ; Pinkerton, Joann V. ; Rowen, Tami S. ; Shapiro, Marla ; Simon, James A. ; Goldfarb, Shari B. ; Kingsberg, Sheryl A. / CONSENSUS RECOMMENDATIONS : Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: Consensus recommendations from the North American Menopause Society and the International Society for the Study of Women's Sexual Health. In: Menopause. 2018 ; Vol. 25, No. 6. pp. 596-608.
@article{a3b0c85d21c74373a43f142fefcb3f1c,
title = "CONSENSUS RECOMMENDATIONS: Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: Consensus recommendations from the North American Menopause Society and the International Society for the Study of Women's Sexual Health",
abstract = "The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. The Expert Consensus Panel is comprised of a diverse group of 16 multidisciplinary experts well respected in their fields. The panelists individually conducted an evidence-based review of the literature in their respective areas of expertise. They then met to discuss the latest treatment options for genitourinary syndrome of menopause (GSM) in survivors of breast cancer and review management strategies for GSM in women with or at high risk for breast cancer, using a modified Delphi method. This iterative process involved presentations summarizing the current literature, debate, and discussion of divergent opinions concerning GSM assessment and management, leading to the development of consensus recommendations for the clinician. Genitourinary syndrome of menopause is more prevalent in survivors of breast cancer, is commonly undiagnosed and untreated, and may have early onset because of cancer treatments or risk-reducing strategies. The paucity of evidence regarding the safety of vaginal hormone therapies in women with or at high risk for breast cancer has resulted in avoidance of treatment, potentially adversely affecting quality of life and intimate relationships. Factors influencing decision-making regarding treatment for GSM include breast cancer recurrence risk, severity of symptoms, response to prior therapies, and personal preference. We review current evidence for various pharmacologic and nonpharmacologic therapeutic modalities in women with a history of or at high risk for breast cancer and highlight the substantial gaps in the evidence for safe and effective therapies and the need for future research. Treatment of GSM is individualized, with nonhormone treatments generally being first line in this population. The use of local hormone therapies may be an option for some women who fail nonpharmacologic and nonhormone treatments after a discussion of risks and benefits and review with a woman's oncologist. We provide consensus recommendations for an approach to the management of GSM in specific patient populations, including women at high risk for breast cancer, women with estrogen-receptor positive breast cancers, women with triple-negative breast cancers, and women with metastatic disease.",
keywords = "Atrophic vaginitis, Breast cancer, Breast cancer risk, Breast cancer survivors, Genitourinary syndrome of menopause, Vulvovaginal atrophy",
author = "Faubion, {Stephanie S.} and Larkin, {Lisa C.} and Stuenkel, {Cynthia A.} and Bachmann, {Gloria A.} and Chism, {Lisa A.} and Risa Kagan and Kaunitz, {Andrew M.} and Krychman, {Michael L.} and Parish, {Sharon J.} and Partridge, {Ann H.} and Pinkerton, {Joann V.} and Rowen, {Tami S.} and Marla Shapiro and Simon, {James A.} and Goldfarb, {Shari B.} and Kingsberg, {Sheryl A.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1097/GME.0000000000001121",
language = "English (US)",
volume = "25",
pages = "596--608",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - CONSENSUS RECOMMENDATIONS

T2 - Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: Consensus recommendations from the North American Menopause Society and the International Society for the Study of Women's Sexual Health

AU - Faubion, Stephanie S.

AU - Larkin, Lisa C.

AU - Stuenkel, Cynthia A.

AU - Bachmann, Gloria A.

AU - Chism, Lisa A.

AU - Kagan, Risa

AU - Kaunitz, Andrew M.

AU - Krychman, Michael L.

AU - Parish, Sharon J.

AU - Partridge, Ann H.

AU - Pinkerton, Joann V.

AU - Rowen, Tami S.

AU - Shapiro, Marla

AU - Simon, James A.

AU - Goldfarb, Shari B.

AU - Kingsberg, Sheryl A.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. The Expert Consensus Panel is comprised of a diverse group of 16 multidisciplinary experts well respected in their fields. The panelists individually conducted an evidence-based review of the literature in their respective areas of expertise. They then met to discuss the latest treatment options for genitourinary syndrome of menopause (GSM) in survivors of breast cancer and review management strategies for GSM in women with or at high risk for breast cancer, using a modified Delphi method. This iterative process involved presentations summarizing the current literature, debate, and discussion of divergent opinions concerning GSM assessment and management, leading to the development of consensus recommendations for the clinician. Genitourinary syndrome of menopause is more prevalent in survivors of breast cancer, is commonly undiagnosed and untreated, and may have early onset because of cancer treatments or risk-reducing strategies. The paucity of evidence regarding the safety of vaginal hormone therapies in women with or at high risk for breast cancer has resulted in avoidance of treatment, potentially adversely affecting quality of life and intimate relationships. Factors influencing decision-making regarding treatment for GSM include breast cancer recurrence risk, severity of symptoms, response to prior therapies, and personal preference. We review current evidence for various pharmacologic and nonpharmacologic therapeutic modalities in women with a history of or at high risk for breast cancer and highlight the substantial gaps in the evidence for safe and effective therapies and the need for future research. Treatment of GSM is individualized, with nonhormone treatments generally being first line in this population. The use of local hormone therapies may be an option for some women who fail nonpharmacologic and nonhormone treatments after a discussion of risks and benefits and review with a woman's oncologist. We provide consensus recommendations for an approach to the management of GSM in specific patient populations, including women at high risk for breast cancer, women with estrogen-receptor positive breast cancers, women with triple-negative breast cancers, and women with metastatic disease.

AB - The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. The Expert Consensus Panel is comprised of a diverse group of 16 multidisciplinary experts well respected in their fields. The panelists individually conducted an evidence-based review of the literature in their respective areas of expertise. They then met to discuss the latest treatment options for genitourinary syndrome of menopause (GSM) in survivors of breast cancer and review management strategies for GSM in women with or at high risk for breast cancer, using a modified Delphi method. This iterative process involved presentations summarizing the current literature, debate, and discussion of divergent opinions concerning GSM assessment and management, leading to the development of consensus recommendations for the clinician. Genitourinary syndrome of menopause is more prevalent in survivors of breast cancer, is commonly undiagnosed and untreated, and may have early onset because of cancer treatments or risk-reducing strategies. The paucity of evidence regarding the safety of vaginal hormone therapies in women with or at high risk for breast cancer has resulted in avoidance of treatment, potentially adversely affecting quality of life and intimate relationships. Factors influencing decision-making regarding treatment for GSM include breast cancer recurrence risk, severity of symptoms, response to prior therapies, and personal preference. We review current evidence for various pharmacologic and nonpharmacologic therapeutic modalities in women with a history of or at high risk for breast cancer and highlight the substantial gaps in the evidence for safe and effective therapies and the need for future research. Treatment of GSM is individualized, with nonhormone treatments generally being first line in this population. The use of local hormone therapies may be an option for some women who fail nonpharmacologic and nonhormone treatments after a discussion of risks and benefits and review with a woman's oncologist. We provide consensus recommendations for an approach to the management of GSM in specific patient populations, including women at high risk for breast cancer, women with estrogen-receptor positive breast cancers, women with triple-negative breast cancers, and women with metastatic disease.

KW - Atrophic vaginitis

KW - Breast cancer

KW - Breast cancer risk

KW - Breast cancer survivors

KW - Genitourinary syndrome of menopause

KW - Vulvovaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=85047749962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047749962&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000001121

DO - 10.1097/GME.0000000000001121

M3 - Review article

AN - SCOPUS:85047749962

VL - 25

SP - 596

EP - 608

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 6

ER -